Eli Lilly and Compan

LLY
Delayed Nyse - 07/19 10:01:32 pm
106.79USD
-1.43%
Prev.108.3400
Open108.5000
High108.5150
Low106.5800
Volume3 232 898
Financials
Sales 2019 22 171 M
EBIT 2019 6 243 M
Net income 2019 8 126 M
Debt 2019 3 031 M
Yield 2019 2,36%
P/E ratio 2019 12,1x
P/E ratio 2020 17,4x
EV / Sales2019 4,57x
EV / Sales2020 4,48x
Capitalization 98 336 M
Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (47.6%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (17.4%);
- veterinary medicine (12.8%);
- cardiovascular...
Sector :
Pharmaceuticals - NEC
Calendar :
2019-07-30 Earnings Release
Trading Rating :
Investor Rating :
Latest news
07/19ELI LILLY AND : Acacia Pharma Group plc - Founder Dr. Julian Gilbert steps down Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession
AQ
07/18ELI LILLY AND : AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer, an Investigational Treatment for Alzheimer's disease
AQ
07/17AC Immune, Lilly Begin Dosing Subject with Tau Morphomer Inhibitor
DJ
07/15ELI LILLY AND COMPANY : - AHS 2019 Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality Show Improvements in Daily Functioning and Reductions in Disability
AQ
07/15ELI LILLY AND : Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine
AQ
07/15ELI LILLY AND : Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
AQ
07/13ELI LILLY AND : Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
PU
07/12ELI LILLY AND COMPANY : - New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality in Episodic Cluster Headache
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishNeutral
Resistance112118130
Spread/Res.-4,4%-9,8%-18%
Spread/Supp.3,8%8,2%1,1%
Support10398,7106